AstraZeneca has entered an agreement with China-based CSPC Pharmaceuticals to advance drug development programs targeting obesity and type 2 diabetes. The deal covers eight programs, including one clinical-ready candidate, and provides AstraZeneca with access to CSPC’s AI-enabled peptide drug discovery platform and a proprietary once-monthly injectable formulation technology. CSPC will continue to manage early-stage development, […]